Introduction
============

In 1932, Richard Shope isolated the first papillomavirus (PV) from crude extracts of "warty" tumors found on the skin of a wild cottontail rabbit ([@B46]). Since then, 183 animal and 225 HPV have been discovered and classified in The Papillomavirus Episteme (PaVE) ([@B54])^[1](#fn01){ref-type="fn"}^ With the advent of metagenomic sequencing, the rate of HPV discovery has accelerated rapidly ([@B10]) and the resolution of HPV viromes and variants have sharpened immensely ([@B44]) to allow in-depth analysis of genetic variations and functional consequences ([@B52]; [@B20]).

The PV is believed to have co-evolved with their hosts over 350 million years ([@B19]). Through phylogenetic analysis, [@B14] demonstrated that viral niche-adaptation to host ecosystems (tissue tropism) anteceded viral-host codivergence. The PV-host tissue tropism apparently played a vital role in shaping the molecular evolution of oncogenic HPV from archaic hominins to modern humans. HPV-16, an extraordinary result of evolutionary processes over the last 40 million years ([@B14]) has emerged as a highly potent carcinogen with a predilection for human mucosa. HPV-16 is now the leading cause of invasive cervical cancer and other cancers of the oropharyngeal and anogenital tracts ([@B6]).

The HPV genome is a ∼8,000 base pair (bp), double stranded, circular DNA packaged within a protein capsid. The prototypical genome encodes 6 early genes (E1, E2, E4, E5, E6, and E7) and 2 late genes (L1 and L2) ([@B54]). Specifically, the L1 gene encodes the major capsid protein which forms a pentameric capsomer that self-arranges into a 72-subunit icosahedral capsid. The capsid is essential for viral binding and entry into host-specific tissues ([@B8]). Furthermore, the L1 coding sequences of the immunogenic surface loops are distinctively poorly conserved due to selective pressures for mutagenesis and immune evasion ([@B8]).

Recently, whole-genome Sanger and deep sequencing studies have shown a surprisingly high level of intra-host diversity of HPV-16, -18, -52, and -58 ([@B52], [@B53]; [@B32]). Extensive intra-host HPV L1 sequence variability in 35 HPV genotypes was also discovered in samples from Zimbabwean women by deep sequencing ([@B20]). Such intra-host viral sequence variability is believed to be caused by error-prone host replication machinery used for viral replication and HPV-induced APOBEC deaminase activity with ensuing selective shaping by host tissues and immune responses ([@B20]; [@B32]). These remarkable findings of L1 genetic variability are clinically important due to potential structural changes on the epitopes of virions arising from nonsynonymous mutations. The result may be ineffectual binding by host neutralizing antibodies induced by either natural infections or prophylactic vaccines ([@B5]; [@B21]).

Using a multi-omics approach, we aimed to explore the HPV genotype composition and intra-genotype variants within individual samples of low and high-grade cervical cytology. We also focused on the genetic and translated amino acid sequence variations of L1 informed by next-generation sequencing (NGS) for mapping onto the structure of HPV antigenic loops as a means of variant profiling and visualization.

Materials and Methods {#s1}
=====================

Subjects and Samples
--------------------

Residual liquid-based cervical cytology samples were consecutively procured from the Department of Pathology after completion of cytological diagnosis. Demographic and cytohistological data were abstracted from the electronic health record (AHLTA) of the Department of Defense (DoD) and linked to each sample. In our previous study, three categories of samples, i.e., negative for intraepithelial lesion or malignancy (NILM), low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) were collected for HPV genotyping and DNA methylation analysis ([@B43]). For this pilot study, we randomly selected a subset of HPV-positive LSIL (*n* = 6) and HSIL (*n* = 6) for characterization and comparison of viral diversity and variant analysis.

HPV L1 DNA Amplification and Deep Sequencing
--------------------------------------------

DNA extraction from residual liquid-based cervical cytology for HPV DNA amplification and deep sequencing was performed as described previously ([@B44]). Briefly, HPV DNA was amplified using the consensus primer set: MY09/11 to target a 450 bp region (corresponding to flanking nucleotide positions 6584/7035 on HPV-16) of the L1 gene for genotype identification ([@B45]). The PCR products were then purified for construction of DNA libraries using the Nextera XT kit (Illumina). Each DNA sample (1 ng) with a standardized concentration of 0.1--0.2 ng/μL was "tagmented" (fragmented and tagged with sequencing adapters) and barcoded with dual index adaptors. The DNA libraries were normalized quantitatively for equal representation from each sample prior to pooling and sequencing. Paired-end bi-directional sequencing (2 × 300 bp) was performed on the MiSeq (Illumina) instrument using the MiSeq Reagent Kit v3 (600-cycle) for bridge amplification. Quality sequences were subjected to nucleotide BLAST ([@B1]) against the HPV sequences in the papillomavirus genome database (PaVE) ([@B54])^[2](#fn02){ref-type="fn"}^, to determine the HPV genotype(s) ([@B45]).

The PCR products were concurrently subjected to dideoxy (Sanger) sequencing for validation of deep-sequenced results. Briefly, amplicons (∼200 ng DNA/sample) were sequenced using primer MY11 at Eurofins Operon (United States). The resulting quality sequences were BLAST aligned for HPV genotyping as described above.

Next-Generation Sequencing (NGS) Data Analysis, Genotyping, and Taxonomic Profiling
-----------------------------------------------------------------------------------

The pre-configured, automated Quality Control (QC) workflow implemented in Illumina MiSeq output a series of QC metrics including the summary statistics of the reads, and the Phred quality scores Q which correspond to the base-calling error probabilities ([@B23]; [@B24]). The reads were processed using the CLC Genomics Workbench 11.0.1 (QIAGEN). The Core NGS workflow was implemented, including: (1) Preprocessing reads with quality trimming based on quality scores with a limit cutoff 0.05, and the ambiguity number ≤2, and adapter trimming. (2) Merging overlapping pairs to improve the read quality. The parameter setting was mismatch cost 2, gap cost 3, and minimum score 8. (3) Mapping to the nonredundant HPV reference genome database, which was constructed based on the collection and annotation of the PaVE database ([@B54]). Mapping parameters included read alignment match score 1, mismatch penalty 2, linear gap cost for insertion or deletion of 3. (4) Taxonomic profiling. The Microbial Genomics Module was implemented to perform qualification by assigning the read to a HPV genotype if a match is found and quantification of the abundance of each qualified HPV genotype to generate an abundance table for each sample. Reads matching to the host genome were filtered.

Diversity Analysis of HPV Communities in LSIL and HSIL Samples
--------------------------------------------------------------

The diversity of the HPV genotypes was analyzed for each sample using the Microbial Genomics Module of the CLC Genomics Workbench 11.01.1 (QIAGEN). α-diversity of the HPV communities was computed to measure within-sample variation by (1) the Simpson's index ([@B47]): $\text{SI}\, = \, 1\, - \,{\sum_{\text{i} = 1}^{n}{\, p_{i}^{2}}}\,$, and (2) Shannon entropy ([@B42]): $\text{H}\, = \,{\sum_{1}^{n}{\, p_{i}}}\text{log}_{2}p_{\text{i}}$, where *n* was the number of HPV genotypes found in the sample, and *p~i~* was the proportion of reads that were identified as the *i^th^* HPV genotype. β-diversity analysis was performed with the principle coordinate analysis (PCoA) of Bray-Curtis distances ([@B7]): $B\, = \,\frac{\sum_{\text{i} = 1}^{n}\left. \, \middle| x_{i}^{A}\, - \, x_{i}^{B} \right|}{\sum_{\text{i} = 1}^{n}{(x_{i}^{A} - x_{i}^{B})}}$, where *n* is the number of operational taxonomic unit (OTU) *i* and $x_{i}^{A}$ and $x_{i}^{B}$ are the respective abundances of OTU *i* in samples *A* and *B*, to measure the dissimilarity or "distance" of HPV genotype composition between samples. Principal component analysis (PCA) was used to determine the correlative relationship between variables (HPV genotypes) in the LSIL or HSIL group. PCA was performed on the covariance matrix of natural log-transformed abundance data \[ln (n +1)\] of HPV genotypes within each sample ([@B39]). Log transformation was applied to reduce the influence (skewness) of highly abundant genotypes. PCA was performed using STATA/IC 15.0 (StataCorp).

Phylogenetic Analysis and Tree Construction of HPV Genotypes
------------------------------------------------------------

Multiple alignment of consensus sequences of each HPV genotype detected in the HSIL and LSIL samples was obtained using the T-coffee program ([@B37]). The evolutionary history of the HPV L1 sequences was inferred by using the Maximum Likelihood (ML) method ([@B25]) and Tamura-Nei model ([@B50]). Initial trees for the heuristic search were obtained automatically by applying Neighbor-Joining (NJ) ([@B40]) and BioNJ ([@B28]) algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The bootstrap resampling with 1,000 pseudo-replicates was carried out to assess support for each individual branch ([@B26]). Bootstrap values of \<50% were collapsed and treated as unresolved polytomies. Evolutionary analyses were conducted in MEGA X ([@B35]).

Detection of HPV L1 Sequence Variants, Amino Acid Alterations, and Structural Modifications
-------------------------------------------------------------------------------------------

Variants were detected by comparing to reference sequences of each HPV type, using the Low Frequency Variant Detection Module in the CLC Bio Genomics Workbench 11.0.1 (QIAGEN), where an error model was included to exclude variants that were likely due to sequencing errors. Variants were classified into four categories: SNV, MNV, indel, or replacement of one or more bases.

The functional consequences of detected variants in each sample were inferred based on the predicted changes at the codon level. These changes were classified as nonsynonymous (with amino acid changes), synonymous (silent mutation without alteration in amino acid designation), or indels which can lead to reading frame shift or early stop codon. To map the amino acid changes to protein structure, BLAST searches were conducted to identify the homologous HPV L1 structure(s) collected in the Protein Data Bank (PDB)^[3](#fn03){ref-type="fn"}^ ([@B2]). 3D models showing the structure of HPV L1 protein with variant and reference sites was created using the CLC Bio Genomics Workbench 11.0.1 (QIAGEN). Another protein structural feature, i.e., surface probability, useful for identification of antigenic determinants was calculated using the protein module of CLC Bio Genomics Workbench 11.0.1 (QIAGEN). The surface probability (accessibility) of an amino acid is predicted using Emini's formula: *S~n~* = \[$\prod_{\text{i} = 1}^{6}$ *δ*~n+4-i~\]∗(0.37)^-6^ where *S~n~* is the surface probability of amino acid *n* equating to the normalized product of fractional surface probabilities (*δ~x~*) of six amino acids flanked by positions *n* -2 and *n*+ 3 ([@B22]). The *S~n~* of a random hexapeptide is 1.0 (threshold); a value \>1.0 indicates increased surface probability.

HPV Taxonomy and Carcinogenicity Classifications
------------------------------------------------

The genotype classification of PV is based on the DNA sequence of the L1 gene ([@B18]; [@B3]). The definitions for taxonomic ranks (PaVE) are as follows: (1) Genera: members of the same genus share \>60% nucleotide sequence identity in the L1 open reading frame (ORF), (2) Species: PV types within a species share between 71 and 89% nucleotide identity within the complete L1 ORF, (3) Genotypes: PV of the same type share ≥90% nucleotide sequence identity, (4) Variants: \<2% sequence difference from a known type, (5) Variant lineage: PV genomes with approximately 1.0% nucleotide sequence difference (proposed nomenclature), and (6) Sub-lineage: PV genomes with 0.5--1.0% nucleotide sequence difference (proposed nomenclature).

The World Health Organization (WHO) International Agency for Research on Cancer (IARC) Working Group assessed carcinogenic potential of HPV types and classified them into three categories ([@B33]) (1) carcinogenic: HPV types 16, 31, 33, 35, 52, and 58 in α-9, HPV types 18, 39, 45, 59, and 68 in α-7, HPV type 51 in α-5, HPV type 56 in α-6, (2) possibly carcinogenic: HPV types 26, 69, and 82 in α-5, HPV types 30, 53, 66 in α-6, HPV types 70, 85, and 97 in α-7, HPV types 67 in α-9, and HPV types 34 and 73 in α-11, and (3) not classifiable/not carcinogenic: The viruses in this group are from α-1, -2, -3, -4, -8, -10, -13, -14/15. HPV types 6 and 11 were not classifiable, and all others were probably not carcinogenic ([@B41]; [@B3]).

Results
=======

Deep Sequencing Resolved Viromes and Genotypes of Mixed HPV Infections for Differentiation Between LSIL and HSIL Samples
------------------------------------------------------------------------------------------------------------------------

This study included 12 cytology samples, classified as LSIL (*n* = 6) and HSIL (*n* = 6) ([Table 1](#T1){ref-type="table"}). The median age of the cohort was 28 years (range, 21--40). For the LSIL group, the median age \[34 years (range, 22--40)\] was slightly greater than that of the HSIL group \[27 years (range, 21--29)\]. Histological results from cervical biopsies or excisions were available for 9 of 12 (75%) samples. Histological validation of the cytology samples showed overall good agreement (78%) ([Table 1](#T1){ref-type="table"}).

###### 

Cytohistological correlation.

                                      Cytohistological correlation              
  ----------------------------------- ------------------------------ ---------- ----------
  **Histology**                       **Total**                      **LSIL**   **HSIL**
                                                                                
  Samples, n                          12                             6          6
  Histology (biopsy or excision)^a^                                             
      Documented, n (%)               9 (75)                         4 (67)     5 (83)
      Not documented, n (%)           3 (25)                         2 (33)     1 (17)
  Histological grade^a^                                                         
      CIN 0, n (%)                    0                              0          0
      CIN I, n (%)                    4 (44)                         3 (75)     1 (20)
      CIN II/III, n (%)               5 (56)                         1 (25)     4 (80)
  Cytohistological agreement^b^                                                 
      Agreement, %                    78                                        
      Expected agreement, %           51                                        
      Kappa                           0.55                                      
      Std. Error                      0.33                                      
  *p*-value                           0.05                                      

CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion.

a

Cervical histopathology is based on the highest grade documented on cervical biopsy or therapeutic excisional biopsy, i.e., cold knife conization (CKC) and loop excisional procedure (LEEP). Absence or presence of pathology reports in the DoD electronic health records was categorized as "Documented" or "Not documented," respectively.

b

Cytohistological agreement was calculated using samples with documented histopathology. LSIL cytology corresponds to CIN I histology; HSIL cytology corresponds to CIN II/III histology.

Both traditional Sanger and NGS platforms were used to detect HPV genotypes and sub-lineages within each sample. Sanger sequencing resolved the single dominant HPV genotype within each sample. Compared to Sanger sequencing, NGS achieved a better resolution in detection of mixed genotypes (up to four in this cohort) and low-abundance genotypes ([Table 2](#T2){ref-type="table"}). Comparing the dominant genotypes and sub-lineages derived from both sequencing methods, the inter-assay agreement was 100%. Tabulated summary of NGS reads is shown in [Table 2](#T2){ref-type="table"}. The median of reads that passed quality check for 12 samples was 328,197. The proportion of merged reads that were mapped to reference HPV genotype (s) ranged from 94.9 to 99.8%.

###### 

HPV L1 sequencing results.

  Sample Info and PCR^a^   Dideoxy seq^b^   Deep sequencing^c^                                                                                                                    
  ------------------------ ---------------- -------------------- ----------- ------ -------- -------- --- ----------- -------- ----------- ------- ----------- ------ ----------- ------
  179                      HSIL             1                    **16** D3   CARC   226981   224923   3   **16** D3   218169   **70** B1   4258    **39** A2   2150               
  305                      HSIL             1                    **53** D1   POSC   447187   434307   4   **53** D1   404329   **18** A5   18828   **66** B1   5095   **70** B1   3197
  313                      HSIL             1                    **16** A4   CARC   462487   456343   1   **16** A4   451363                                                      
  319                      HSIL             1                    **16** A4   CARC   521199   493925   2   **16** A4   466086   **70** B1   24150                                  
  386                      HSIL             1                    **83**      NC     283025   282650   2   **83**      278890   **16** A4   2015                                   
  399                      HSIL             1                    **16** A4   CARC   240743   239279   1   **16** A4   238954                                                      
  81                       LSIL             1                    **58** C1   CARC   120075   119929   2   **58** C1   91062    **61**      28293                                  
  137                      LSIL             1                    **66** A1   CARC   459454   458465   1   **66** A1   457259                                                      
  138                      LSIL             1                    **81**      NC     323374   323167   2   **81**      295600   **83**      24988                                  
  140                      LSIL             3                    **61**      NC     112792   112662   3   **61**      102636   **39** A1   8525    **62**      1075               
  141                      LSIL             1                    **53** A1   POSC   255851   254268   2   **53** A1   247587   **61**      4781                                   
  160                      LSIL             1                    **16** A4   CARC   429808   428796   2   **16** A4   417946   **18** A5   10551                                  

CARC, carcinogenic HPV; HSIL, high-grade squamous intraepithelial lesion; HPV, human papillomavirus; ID, sample identification; IARC Carc, International Agency for Research on Cancer -- classification of carcinogenicity; L1, HPV L1 gene amplified by PCR; LSIL, low-grade squamous intraepithelial lesion; PCR, polymerase chain reaction; POSC, possibly carcinogenic; NC, not classifiable/probably not carcinogenic; Sample ID No., sequentially numbered samples grouped as LSIL or HSIL; PAP, Pap smear; Seq, sequencing.

a

Cytologically derived DNA samples amplified by PCR using consensus primers to target the HPV L1 loci. The number of PCR amplicon bands was determined by high-resolution capillary gel electrophoresis.

b

HPV genotype determined by BLAST alignment after amplicon sequencing (dideoxy method). HPV genotype number in bold and sub-lineage in alphanumeric fonts.

c

HPV genotype determined by BLAST alignment after amplicon sequencing (deep method). HPV genotype number in bold and sub-lineage in alphanumeric fonts.

HPV Communities Were Dissimilar Between LSIL and HSIL With Loss of Species Richness and Gain of HPV-16 Dominance in HSIL Samples
--------------------------------------------------------------------------------------------------------------------------------

The composition of HPV genotypes in each sample is illustrated in [Figure 1](#F1){ref-type="fig"}. For six LSIL L1 samples, the number of genotype(s) per sample was distributed as: 1 (16.7%), 2 (66.6%), and 3 (16.7%). For six HSIL samples, the number of genotype(s) per sample was distributed as: 1 (33.3%), 2 (33.3%), 3 (16.7%), and 4 (16.7%). Notably, all HSIL samples contained at least one carcinogenic HPV genotype, whereas only half of the LSIL samples were found to have a carcinogenic genotype ([Table 2](#T2){ref-type="table"}).

![HPV genotype composition found in LSIL and HSIL samples. Deep sequencing of HPV L1 amplicons derived from each LSIL or HSIL sample identified one to four HPV genotypes and quantitated their composition (%) based on number of mapped reads to total mapped reads. Each sample contained a dominant genotype. For HSIL, HPV-16 prevailed in 4 of 6 (67%) samples. In contrast, a mixture of carcinogenic, possibly carcinogenic and probably not carcinogenic HPV genotypes (33% for each category) were identified in LSIL samples. The HPV carcinogenicity is based on IARC's classification of human carcinogens ([@B33]). Carc, carcinogenic; HSIL, high-grade squamous intraepithelial lesion; IARC, International Agency for Research on Cancer; ID, identification; LSIL, low-grade squamous intraepithelial lesion.](fgene-10-00489-g001){#F1}

We analyzed the HPV diversity, dominance and community structure between LSIL and HSIL samples. A total of 10 different genotypes were found in single and mixed-infected LSIL samples, whereas seven different genotypes were identified in HSIL samples. The respective Shannon Entropy Indices for LSIL and HSIL samples were 0.32 and 0.16, suggesting reduced diversity in HSIL samples ([Figure 2](#F2){ref-type="fig"}). The dominant (most abundant) genotype in LSIL samples was HPV-61 versus HPV-16 for HSIL. HPV-16, one of the most important carcinogens responsible for almost half of the cervical cancer incidences ([@B51]; [@B36]), was found in 5 of 6 (83.3%) HSIL samples. Two additional carcinogenic genotypes HPV-18 and HPV-39 were also discovered in HSIL samples. By contrast, HPV-61, which was considered noncarcinogenic, had 50% occurrence in LSIL samples, indicative of low risk for cervical cancer ([@B41]). It is worthy to note that two LSIL samples contained carcinogenic genotypes (HPV-58 in Sample 81, and HPV-16 in Sample 160), suggesting a finer resolution by HPV molecular profiling than cytological grading for carcinogenic potential.

![HPV diversity analysis for LSIL and HSIL based on L1 deep sequencing. A total of 10 genotypes out of 6 samples were found in LSIL versus 7 genotypes out of 6 samples for HSIL. The respective Shannon Entropy Indices for LSIL (dashed line) and HSIL samples (solid line) were 0.32 and 0.16, suggesting reduced diversity in HSIL samples. Similarly, species richness measured by Simpson's index showed a reduction in high-grade cytology (0.12 vs. 0.05 for LSIL and HSIL, respectively). Two samples (137 and 399) contained pure species or zero diversity are indicated by arrowheads. The dominant (most abundant) genotype in LSIL samples was HPV-61 versus HPV-16 for HSIL.](fgene-10-00489-g002){#F2}

We further examined the diversity of each sample estimated through read counts and Simpson-Index ([Figure 2](#F2){ref-type="fig"}). The reduced diversity in high grade cytology samples is supported by the mean Simpson's indices (0.12 versus 0.05 for LSIL and HSIL, respectively). Sample 81 showed a relatively high diversity among LSIL samples, likely due to the presence of two abundant genotypes HPV58 and HPV 61. Sample 305 had the highest diversity in HSIL samples with mixed infection of four genotypes (carcinogenic HPV18, and possibly carcinogenic HPV53, HPV 66, and HPV 70). Samples with pure HPV genotypes, 137 and 399, exhibited low diversity.

Dissimilarity of HPV communities across HSIL and LSIL samples was visualized by principle coordinate analysis (PCoA) of Bray-Curtis distances ([@B7]; [Figure 3](#F3){ref-type="fig"}). PCoA showed HPV-16 (PCo 1, 60%) as being the most influential genotype in HSIL. In contrast, LSIL was influenced about equally (PCo 1--3, 21--26%) by carcinogenic, possibly carcinogenic, and probably not carcinogenic/not classifiable genotypes. As for the PCA results, the component loadings plot for LSIL and HSIL showed the correlative relationship between HPV genotypes along the first two principal components axes (PC1 and PC2) ([Supplementary Figure 3](#SM4){ref-type="supplementary-material"}). The sum of PC1 and PC2 explained 51.6 and 96.2% of the total variance for LSIL and HSIL, respectively. Comparing LSIL and HSIL, HPV-16 emerged from all other genotypes as the dominant component in HSIL. The score variables plots displayed each sample's contribution to the principal components. HSIL compared to LSIL had a preponderance of samples containing a high composition of HPV-16.

![HPV dominance and community structure between LSIL and HSIL. HPV L1 3D-Principal Coordinate Analysis (PCoA) plots of HSIL and LSIL samples showing dissimilarity between the two HPV communities with HPV-16 (PCoA 1) being the most influential genotype in HSIL versus HPV-61 for LSIL (PCoA 1). β-diversity was measured by Bray-Curtis index. Carc, carcinogenic; HSIL, high-grade squamous intraepithelial lesion; ID, identification; LSIL, low-grade squamous intraepithelial lesion.](fgene-10-00489-g003){#F3}

Molecular Taxonomy of HPV Genotypes Based on NGS Is Highly Discriminatory and Correlated With IARC-Defined Carcinogenicity
--------------------------------------------------------------------------------------------------------------------------

Prototypical HPV genome based on the genetic information of HPV-16 (GenBank ID: K02718) is created using the CLC Bio Genomics Workbench 11.0.1 (QIAGEN) and shown in [Figure 4](#F4){ref-type="fig"}. The L1 (450 bp) gene fragment of each sample was the target used for sequencing, genotyping, and phylogenetic analysis. A maximum likelihood tree was inferred from the L1 sequences derived from single and multi-infected samples ([Figure 5](#F5){ref-type="fig"}). The tree topology is consistent with the HPV species trees ([@B41]; [@B3]; [@B33]). These L1 sequences were clustered into four clades with strong bootstrap support: (1) α-9 clade included HPV-16 from four HSIL and two LSIL samples, and HPV-58 from an LSIL sample 81. Both HPV-16 and HPV-58 are carcinogenic. (2) α-7 clade included carcinogenic HPV-18 and HPV-39, and a possibly carcinogenic HPV-70, which were shown in three mixed-infected HSIL samples. (3) α-6 clade included possibly carcinogenic HPV-53 and HPV-66. (4) α-3 clade included all the probably not carcinogenic genotypes found in HSIL and LSIL samples ([@B15]). Clearly, the broad categorical grade designation based on precancerous cervical lesions (HSIL versus LSIL) was imprecise at predicting carcinogenicity. Conversely, the molecular taxonomy based on NGS is highly discriminatory and correlated well with IARC-defined carcinogenicity.

![Prototypical HPV genome based on the genetic information of HPV-16 (GenBank ID: K02718). The L1 (450 bp) gene segment of each sample was the target used for sequencing, genotyping, and phylogenetic analysis.](fgene-10-00489-g004){#F4}

![Evolutionary relationships of HPV L1 sequences derived from LSIL and HSIL samples. Phylogenetic tree of L1 nucleotide sequences revealed clades of species (-6, 7, 9) \[black bracket\] and -3 \[green bracket\] within the -genus, correlating with the level of IARC-defined carcinogenicity. Between individual samples (sample ID-HPV*n*), HPV intra-type genetic differences are prevalent as distinguished by nonoverlapping branches. The evolutionary history of the HPV L1 sequences was inferred by using the Maximum Likelihood method ([@B25]) and Tamura-Nei model ([@B50]). The tree with the highest log likelihood (-7492.54) is shown. The percentage of trees in which the associated taxa clustered together is shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Joining ([@B40]) and BioNJ ([@B28]) algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. Bootstrap resampling with 1,000 pseudo-replicates was carried out to assess support for each individual branch ([@B26]). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. Evolutionary analyses were conducted in MEGA X ([@B35]). Carc, carcinogenic; NC, not classifiable; Poss Carc, possibly carcinogenic; Prob Not Carc, probably not carcinogenic; REF, reference genome; URR, upstream regulatory region.](fgene-10-00489-g005){#F5}

Sequence and Structural Variations Identified at HPV Antigenic Sites May Alter Viral Recognition by Innate or Vaccine-Induced Host Defense
------------------------------------------------------------------------------------------------------------------------------------------

We hypothesized that variation in HPV L1 within and among the clinical samples can reveal critical details about the genetic basis for evolution of HPV immune evasion and host-pathogen interactions, because L1 encodes the major capsid protein that plays an important role in virion attachment and entry to the host ([@B34]; [@B17]; [@B49]; [@B12]). Being a natural antigen, the capsid surface is the target of HPV prophylactic vaccines ([@B30]; [@B31]; [@B55]). [Supplementary Table 1](#SM1){ref-type="supplementary-material"} lists the position, predicted mutation type and change at the coding region for HPV variants, compared to the respective reference HPV types. For the combined LSIL/HSIL samples (*n* = 12), a total of 417 mutations were detected, including 375 SNVs, 29 indels, 12 MNVs, and one replacement variant. The distribution of these variants for the 12 samples by Pap grade and HPV genotype is shown in [Figure 6A,B](#F6){ref-type="fig"}, respectively. The proportion of nonsynonymous mutations was lower for HSIL (0.38) than for LSIL samples (0.51) (*p* = 0.017, Fisher's exact test) ([Figure 7](#F7){ref-type="fig"}). On the other hand, probably or probably not carcinogenic HPV types in LSIL samples appeared to be under relaxed functional constraint to accumulate mutations. The distribution of variants in HPV L1 by amino acid positions according to HPV genotype is shown in [Supplementary Figure 1](#SM2){ref-type="supplementary-material"}.

![Distribution of variants in HPV L1 sequences. **(A)** Distribution of variants by Pap grade. The predominant type of variants identified in LSIL (*n* = 6) and HSIL (*n* = 6) samples was single nucleotide variant (SNV). **(B)** Distribution of variants by HPV genotype. Eleven HPV genotypes were identified in the deep sequenced LSIL/HSIL (*n* = 12) samples. The top three genotypes with the highest total number of variants were HPV-16, -61, and -70. DEL, deletion; INS, insertion; MNV, multi-nucleotide variant (two or more SNVs in succession); REP, replacement; SNV, single nucleotide variant.](fgene-10-00489-g006){#F6}

![Distribution of variants in HPV L1 sequences found in HSIL and LSIL samples. Variants are categorized as nonsynonymous, synonymous, and insertion/deletion and displayed as frequency counts. The proportion of nonsynonymous mutations was lower for HSIL (0.38) than for LSIL samples (0.51) (*p* = 0.017, Fisher's exact test). This finding suggests that the inherent competitive advantage of carcinogenic HPV genotypes, e.g., HPV-16 further shaped by intra-host selection may contribute to viral carcinogenesis. One replacement variant of HPV-39 discovered in Sample 140 is not shown in the figure. The annotated variant table including predicted amino acid changes is presented in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}. HSIL, high-grade squamous intraepithelial lesion; ID, identification; INDEL, insertion/deletion; LSIL, low-grade squamous intraepithelial lesion; NONSYN, nonsynonymous; SYN, synonymous.](fgene-10-00489-g007){#F7}

It is important to identify mutations that is potentially driven by vaccine- or natural infection-induced host immune response. To visualize mutations in 3D, first the structural model of HPV-16 L1 (PDB ID: 2R5H) ([@B4]) was reconstructed with demarcated hypervariable surface loops: BC, DE, EF, FG, and HI ([Figure 8](#F8){ref-type="fig"}). Additionally, the HPV-16 L1 protein sequence with surface probability plot for prediction of antigenic determinants on surface proteins ([@B22]) is provided in [Supplementary Figure 2](#SM3){ref-type="supplementary-material"}. In the case of HSIL Sample 179, we identified seven nonsynonymous mutations in HPV-16. [Figure 9](#F9){ref-type="fig"} shows 3D conformational changes visualized by overlying the mutated amino acid residues (cyan) to those (purple) in the reference HPV-16 structure (PDB ID: 1DZL) ([@B13]). It is particularly noticeable that the mutation at position 353 corresponded to a threonine to proline change (T353P) located at the HI-Loop. The T353P change also increased the surface probability from 3.40 to 3.63 (range, 0--6.47; threshold = 1.0) ([Supplementary Figure 2](#SM3){ref-type="supplementary-material"}). HI Loop is one of the loops in L1 protein that extends to the outer surface of the capsid complex ([@B13]; [@B4]). This hypervariable HI loop (AA 339--365) contains an HPV-16 immunodominant epitope ([@B16]). As seen in human Influenza virus, antigen drift, where mutations are accumulated in antigenic sites, is a potent force driving the evolution of immune evasion and reduced vaccine efficacy ([@B27]; [@B9]; [@B48]). Similarly, codon changes like T353P at the antigenic regions may confer selective advantage by increasing the likelihood of immune evasion. In addition to T353P, other mutations in this sample may lead to changes in the secondary structure, including W325C at G2 β-sheet, G367P at β-I sheet, T389S at α-2 helix, L441I at a β-turn, Q461P and F462Y near α-5 helix ([@B4]).

![Structure of HPV-16 L1 capsomer. Structural model of HPV-16 L1 capsomer reconstructed from the coordinates and crystal structure filed in Protein Data Bank (PDB ID: 2R5H) ([@B4]). The capsomer composed of five L1 subunits (numbered 1--5) are displayed in backbone and surface views to highlight the hypervariable surface loops: BC, DE, EF, FG, and HI and amino acid (AA) positions. These loops are antigenic regions of interest in vaccinology.](fgene-10-00489-g008){#F8}

![Structural location of L1 variants. Visualization of L1 variants from a HSIL sample (Sample 179) linked to a 3D protein structure. The reference structure is a HPV 16 L1 monomer with accession number 1DZL ([@B13]) shown in backbone representation. Variant consequences in 3D are identified by the variant in cyan collocated on top of the reference amino acid in purple with attention toward the surface loops. AA, amino acid position.](fgene-10-00489-g009){#F9}

Discussion
==========

This study revealed the complex genetic diversity of HPV viromes within low- and high-grade Pap samples. Both pure and mixed infections were common as shown by deep amplicon sequencing. Taxonomic profiling revealed the difference between LSIL and HSIL viral communities with loss of species richness and gain of dominance by carcinogenic genotypes, particularly HPV-16, in HSIL samples. Deep sequencing allowed the detection of carcinogenic HPVs constituting a minor component of a virome which was undisclosed by Sanger sequencing or cytological grading. Phylogenetic inference of the patient-derived L1 sequences showed excellent correlation between HPV type-specific distances and IARC-defined carcinogenic potential. Together with taxonomic profiling, this "Taxo-Phylo" approach holds promise as a molecular taxonomy-based classifier of cervical cytology.

HPV variant detection and analysis pinpointed the nucleotide-level mutations and potential functional, as well as, structural consequences. Localizing mutations to primary sequences and structures can help understand the functional consequence of mutations and identify causal or adaptive mutations. Furthermore, *in silico* modeling of mutations may direct laboratory testing and confirmation of its significance through antigen-antibody binding assays. For example, hepatitis B virus (HBV) genotypes are known to vary by ethno-geography. Mutations in the major hydrophilic regions (MHR) of the hepatitis B surface antigen (HBSAg) have resulted in stable, vaccine-escape mutant virions that are infectious and pathogenic ([@B11]; [@B29]). Recently, investigators have used ultra-deep sequencing and clinical immunoassays (monoclonal antibodies) to detect single-nucleotide, vaccine-escape mutations and associated changes in the HBSAg amino acid residues in clinical samples ([@B29]). Similarly, liquid-based cervical cytology samples may be interrogated by deep sequencing and multiplexed immunoassays, e.g., Luminex xMAP^®^ ([@B38]) to survey HPV L1 mutant virions that may escape from innate or vaccine-induced immunity.

Longitudinal HPV metagenomic surveillance may also provide a sensitive means of detecting changes in HPV evolution and dynamics within individuals or populations. This is clinically important because virulent genotype(s) of low abundance may later dominate the virome if it is inherently more carcinogenic or confers a selective advantage with ensuing clonal expansion. Current published literature on HPV L1 variant analysis is scarce. As noted previously, a high intra-type L1 sequence variability was discovered in 35 HPV genotypes by deep sequencing. These investigators also found unique genotypes and its variants associating with distinct anatomical sites supporting the notion of viral niche-adaptation as shapers of viral evolution ([@B14]; [@B20]). However, functional consequences of these mutations were not studied. Another investigation found multiple mutations within the L1 fragment of HPV-16 (MY09/11-primed amplicons) of 35 invasive cervical cancer samples from Morocco ([@B21]). A distinct mutation in the HI loop (T389P) found in 51.4% of cases could potentially interact with vaccine-induced neutralizing antibodies ([@B21]). In view of this information, our results are highly consistent with the findings of high intra-host and intra-type L1 sequence variability that could potentially impact vaccine efficacy.

The strength of this study lies in the multi-omics approach developed herein. Integration of clinical metadata, genomic data, and functional/structural information to reveal patient-specific metagenomic profiles and variant structures in 3D is novel and practical. Such individualized virome profiling may provide guidance to clinicians on the risk of cervical cancer and potentially deleterious viral variants/mutations. We acknowledge that our study has limitations in that the sample size was small and a fragment of L1 was studied so overreaching generalizable conclusions cannot be drawn. However, an integrated, holistic approach was established from this dataset to further HPV metagenomics research. Our future direction will be to conduct a large scale, whole-genome or full-sequence L1 variant analysis to survey type-specific variant patterns by cytological grades.

Conclusion
==========

In this pilot study, NGS provided a cost-effective platform for an unbiased discovery of HPV communities in clinical samples. The HPV genotype composition was shown to be correlated with clinical severity and the carcinogenic risk for cervical cancer. Multi-omics analyses afforded an unprecedented opportunity to better characterize the L1 complexity in clinical samples. Ultimately, this approach will lead to greater understanding of the dynamic interplay between virus and host in HPV pathogenesis.
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